黄芩苷对耐药HL-60/ADR细胞及HL-60细胞裸鼠异种移植瘤的实验研究
|
摘要
目的(1)研究中药黄芩苷(Baicalin)对耐阿霉素人髓系白血病HL-60/ADR细胞株增殖、凋亡的影响。观察黄芩苷对HL-60/ADR细胞增殖、凋亡相关基因、凋亡相关蛋白表达及在PI3K/Akt/mTOR、MAPK信号转导通路中蛋白表达水平的影响,探讨其作用机制。(2)研究黄芩苷对HL-60/ADR细胞耐药相关基因和相关蛋白表达的影响,探讨其是否具有逆转耐药的作用及可能机制。(3)研究黄芩苷对高致瘤HL-60细胞裸鼠异种移植瘤的作用。
方法(1)应用MTT法绘制细胞生长曲线、细胞克隆形成实验观察黄芩苷对HL-60 /ADR细胞增殖的影响;Annexin V/PI双染流式细胞检测、DNA倍体分析、末端缺口原位标记(TUNEL)法及DNA凝胶电泳分析细胞凋亡及细胞周期变化;RT- PCR检测黄芩苷作用前后c-myc、bcl-2、hTERT、pim-2、mcl-1、p21等凋亡相关基因mRNA表达水平的变化,蛋白印迹法(Western-Blot)检测c-myc、bcl-2、bad、caspase-3、PARP等凋亡相关蛋白和PI3K/Akt/mTOR、MAPK信号通路相关蛋白表达水平的变化。(2)采用MTT法分别检测阿霉素、柔红霉素、阿糖胞苷、足叶乙甙对HL-60细胞和HL-60/ADR细胞增殖的抑制效应,以及加用黄芩苷时上述抑制作用的变化,并计算逆转倍数。RT-PCR和Western Blot检测黄芩苷作用后HL-60/ADR细胞耐药相关基因和相关蛋白的表达,流式细胞术检测黄芩苷作用前后HL-60/ADR细胞阿霉素蓄积水平。(3)构建高致瘤HL-60细胞裸鼠移植瘤模型,将荷瘤裸鼠随机分为6组:阴性对照组、25mg/kg黄芩苷组、50mg/kg黄芩苷组、100mg/kg黄芩苷组、联合用药组(50mg/kg黄芩苷+2mg/kg VP16)和VP16阳性对照组(4mg/kg)。计算平均瘤重及抑瘤率。通过电镜观察瘤组织超微结构,病理组织学观察裸鼠各主要脏器结构改变,瘤块组织蛋白检测信号转到通路指标。观察裸鼠生存时间。
结果(1)细胞生长曲线结果显示黄芩苷能明显抑制HL-60/ADR细胞增殖,半数抑制浓度(IC50)约为28μmol/L;较低浓度黄芩苷即可抑制HL-60/ADR细胞集落的形成;Annexin V FITC/PI法检测到早期凋亡细胞,DNA片段化、TUNEL法检测到晚期凋亡细胞,细胞凋亡率呈浓度依赖性。细胞周期分析显示,与对照组比较,40μmol/L、80μmol/L浓度组细胞被阻滞于G0/G1期比率明显增高(P<0.01),S期细胞比率降低(P<0.01),各浓度组均检测到典型的亚二倍体峰(凋亡峰)。黄芩苷作用后HL-60/ADR细胞c-myc、bcl-2、hTERT、pim-2、mcl-1基因mRNA表达随着作用时间的延长而逐渐减少;p21基因mRNA表达随着作用时间的延长而逐渐升高。Western-Blot的结果显示c-myc、bcl-2、caspase-3(35kD)和PARP(116kD)蛋白的表达水平呈时间依赖性下降,而caspase-3(17kD、19kD)、PARP(85kD)及bad蛋白的表达则随着作用时间的延长逐渐升高。黄芩苷下调了HL-60/ADR细胞的PI3K/Akt/mTOR和MAPK信号通路蛋白中p-Akt、NF-κB、p-NF-κB、p-IκB-α、mTOR、p-mTOR、p-GSK-3β、p-MAPK的表达,而Akt、IκB-α、GSK-3β和MAPK的表达与对照组相比无明显改变。(2)黄芩苷能部分逆转HL-60/ADR细胞的多药耐药性,阿霉素和黄芩苷联合应用对HL-60/ADR细胞的增殖抑制率明显低于单用阿霉素者,阿霉素单用及联合黄芩苷对HL-60细胞的增殖抑制率没有影响。黄芩苷能下调mrp-1、lrp、GSTπ基因mRNA和mrp-1、GSTπ蛋白的表达,上调TopoⅡα和TopoⅡβ基因mRNA的表达(p<0.05)。而TopoⅠ基因在各组间表达无明显差别。同时观察到黄芩苷能使染上阿霉素荧光的HL-60/ADR细胞比例增加。(3)黄芩苷可抑制裸鼠HL-60细胞皮下移植瘤的生长,呈剂量依赖性。100mg/kg黄芩苷组和联合用药组(50mg/kg黄芩苷+2mg/kg VP16)的瘤块重量明显低于阴性对照组(p<0.01)。瘤组织病理组织学和透射电镜检查结果显示:黄芩苷用药组和联合用药组的肿瘤坏死和细胞凋亡现象较阴性对照组多见。黄芩苷可能通过抑制Akt活性,下调p-Akt、mTOR和p-mTOR的表达来抑制裸鼠异种移植瘤的增长;联合用药组中位生存期明显高于阴性对照组(p<0.05),提示黄芩苷与VP16具有协同抗HL-60细胞裸鼠异种移植瘤的作用。黄芩苷对裸鼠一般状况和体重无不良影响,对裸鼠无明显毒副作用。
结论(1)黄芩苷能有效抑制HL-60/ADR细胞增殖,诱导其凋亡。其机制可能与下调c-myc、bcl-2、hTERT、pim-2、mcl-1 mRNA和/或蛋白表达,上调p21、bad的表达有关。PI3K/Akt/mTOR、MAPK信号通路的改变可能参与了黄芩苷抑制HL-60/ADR细胞增殖、诱导凋亡的过程。(2)黄芩苷能部分逆转HL-60/ADR细胞的耐药性,其机制可能与下调mrp-1、lrp、GSTπ基因mRNA和/或蛋白表达,上调TopoⅡα和TopoⅡβ基因mRNA的表达,增加细胞内药物蓄积水平有关。(3)黄芩苷可抑制高致瘤HL-60细胞裸鼠异种移植瘤的生长,诱导瘤组织中HL-60细胞的凋亡,提高荷瘤裸鼠的中位生存期,其机制之一可能与下调PI3K/Akt/mTOR信号通路有关;黄芩苷与VP16联用具有协同抗HL-60细胞裸鼠异种移植瘤的作用。
Objective(1)To study the effects of baicalin on proliferation inhibition and apoptosis induction on adriamycin-resistant human myeloid leukemia cell line HL-60/ADR cells and on expressions of related apoptotic proteins and mRNA,and to study the change of PI3K/Akt/mTOR,MAPK signal pathway in baicalin-induced HL-60/ADR cells.(2)To investigate the effects of baicalin on the expression of drug-resistance related genes in HL-60/ADR cells and explore its reversal mechanism (.3)To observe the effects of baicalin on HL-60 cell xenografts in nude mice.
Methods(1)HL-60/ADR cells were in vitro cultured and exposed to baicalin at different dosages.Its proliferation inhibition and colony formation were detected by MTT assay and colony formation assay respectively.The cell apoptosis was tested by Annexin V FITC/PI double staining analysis, cell cycle analysis, DNA fragmentation and TUNEL labeling method.RT-PCR was used to analyze the c-myc, bcl-2, hTERT, pim-2, mcl-1 and p21 mRNA expression.The expressions of apoptosis related proteins and signaling molecular PI3K/AKT proteins were examined by western blot.(2)The effect of Adriamycin (ADR),Daunorubicin (DNR) ,Cytarabine (Ara-C) and Etoposide (VP16) on the proliferation of HL-60 and HL-60/ADR cells were observed by MTT assay.The inhibitory effects of all these chemotherapeutic agents used alone or incomebination with baicalin on the proliferation of HL-60 and HL-60/ADR cells were evaluated by MTT assay. The reversal fold of drug resistance was calculated. The expressions of mrp-1, lrp,GSTπ,TopoⅠ,TopoⅡαand TopoⅡβmRNA were measured by RT-PCR.The proteins level of mrp-1 and GSTπwere detected by western blot.The positive rate of ADR fluorescence was analyzed by flow cytometry.(3)Xenograft tumor model of HL-60 cell in nude mice was established,which was divided randomly into six groups:negative control group (5%NaHCO3 group),25mg/ kg baicalin group,50mg/kg baicalin group,100mg/kg baicalin group,combination group (50mg/kg baicalin+2mg/kg VP16),VP16 positive control group(4mg/kg). Nude mice growth state was observed, average weigh and inhibition rate of transplanted tumor were calculated, and the ultramicrostructure change of xenografts cells were tested by transmission electron microscope .Histopathology were used to observed the change of chief organs in nude mice.The expression of Akt, p-Akt, mTOR and p-mTOR proteins extracted from xenografts were detected by western blot. The effects of balcalin on survival rate and median survival time in nude mice with HL-60 cell xenografts were evaluated.
Result(s1)Baicalin effectively inhibited HL-60/ADR cells, proliferation, with an IC50 value of 28μmol/L.Cell colony formation was obviously inhibited by baicalin. Apoptosis occurred with dose dependent manners(20μmol/L, 40μmol/L,80μmol/L), and its earlier and later stages were both detected by Annexin V FITC/PI double staining analysis, DNA fragmentation and TUNEL labeling method. G0/G1 phase cell population increased while S phase cells decreased in 40μmol/L and 80μmol/L groups compared with control group(P<0.01).The typical hypo-diploid peak (apoptotic peak) appeared in each dose group.The mRNA expressions of c-myc, bcl-2, hTERT,pim-2 and mcl-1 in baicalin treated cells decreased in a time-dependent manner(12h,24h, 48h), while the p21 mRNA expression increased. Meanwhile, protein expressions of c-myc, bcl-2, caspase-3(35kD)and PARP(116kD)were down-regulated in a time- dependent manner, and the expressions of caspase-3(17kD,19kD),PARP(85kD) and bad were up-regulated.Moreover,western blot showed the expressions of p-Akt, NF-κB, p-NF-κB, p-IκB-α, mTOR, p-mTOR, p-GSK-3βand p-MAPK protein decreased in HL-60/ ADR cells after baicalin treatment , but the expression of Akt , IκB-α, GSK-3βand MAPK showed no difference compared to control group(.2)The multidrug resistance (MDR) in HL-60/ADR cells can be partially reversed by baicalin. Proliferation inhibition of ADR incombination with baicalin on the HL-60/ADR cells were significantly lower than that of ADR used alone, there was no difference of proliferation inhibition on HL-60 cells between ADR used alone and ADR incombination with baicalin.Baicalin could down-regulate the expression level of mrp-1, lrp,GSTπmRNA and mrp-1, GSTπprotein, and up-regulate TopoⅡαand TopoⅡβmRNA(p<0.05), but TopoⅠdid not change obviously. Furthermore,it was found that baicalin could elevated positive rate of ADR fluorescence in HL-60/ADR cells.(3)Baicalin could inhibit the growth of transplanted tumors in dose dependent manner.The transplanted tumor weight in 100 mg/kg baicalin group and combination group(50mg/kg baicalin+2mg/kg VP16) were significantly lower than that in negative control group(p<0.01) .There were more necrotic and apoptotic cells in baicalin treatment groups and combination group than that in negative control group by histopathology and transmission electron microscope methods.Baicalin could inhibit the proliferation of HL-60 cells in vivo by down-regulating the PI3K/Akt/mTOR signal pathway, where the expressions of p-Akt, mTOR and p-mTOR proteins decreased compared to negative control group, and Akt did not change significantly. Baicalin could prolong the median survival time of nude mice.Compared with negative control group, the median survival time in combination group was significantly different(p<0.05), which illustrated that baicalin combinated with VP16 have the synergistic effect on inhibiting growth of HL-60 cell xenografts in nude mice. The baicalin administration was well tolerated by the nude mice, and no significantly adverse effect was shown.
Conclusion(1)Baicalin could efficiently inhibit proliferation and induce apoptosis in HL-60/ADR cells, which could be correlated with the down-regulated expressions of c-myc,bcl-2,hTERT, mcl-1, and up-regulated expressions of p21and bad. PI3K/Akt /mTOR and MAPK signal pathways may have involved in the process of proliferation inhibition and apoptosis in HL-60/ADR cells induced by baicalin.(2)Baicalin could partially reverse the multidrug resistance of HL-60/ADR cell, and the reversal effect may be related with the reduction of the expression of mrp-1, lrp, GSTπmRNA or protein, increase of TopoⅡαand TopoⅡβmRNA expression level, and elevation of drug accumulation in HL-60/ADR cells.(3)Baicalin could inhibit growth and induce apoptosis of HL-60 cell xenografts in nude mice, and prolong its median survival time. The possible mechanisms may be related to inhibition of Akt activity and down- regulation ation of the PI3K/Akt /mTOR signal pathway. The combination of baicalin and VP16 shows a synergistic effect on inhibiting growth in HL-60 cell xenografts in nude mice.
方法(1)应用MTT法绘制细胞生长曲线、细胞克隆形成实验观察黄芩苷对HL-60 /ADR细胞增殖的影响;Annexin V/PI双染流式细胞检测、DNA倍体分析、末端缺口原位标记(TUNEL)法及DNA凝胶电泳分析细胞凋亡及细胞周期变化;RT- PCR检测黄芩苷作用前后c-myc、bcl-2、hTERT、pim-2、mcl-1、p21等凋亡相关基因mRNA表达水平的变化,蛋白印迹法(Western-Blot)检测c-myc、bcl-2、bad、caspase-3、PARP等凋亡相关蛋白和PI3K/Akt/mTOR、MAPK信号通路相关蛋白表达水平的变化。(2)采用MTT法分别检测阿霉素、柔红霉素、阿糖胞苷、足叶乙甙对HL-60细胞和HL-60/ADR细胞增殖的抑制效应,以及加用黄芩苷时上述抑制作用的变化,并计算逆转倍数。RT-PCR和Western Blot检测黄芩苷作用后HL-60/ADR细胞耐药相关基因和相关蛋白的表达,流式细胞术检测黄芩苷作用前后HL-60/ADR细胞阿霉素蓄积水平。(3)构建高致瘤HL-60细胞裸鼠移植瘤模型,将荷瘤裸鼠随机分为6组:阴性对照组、25mg/kg黄芩苷组、50mg/kg黄芩苷组、100mg/kg黄芩苷组、联合用药组(50mg/kg黄芩苷+2mg/kg VP16)和VP16阳性对照组(4mg/kg)。计算平均瘤重及抑瘤率。通过电镜观察瘤组织超微结构,病理组织学观察裸鼠各主要脏器结构改变,瘤块组织蛋白检测信号转到通路指标。观察裸鼠生存时间。
结果(1)细胞生长曲线结果显示黄芩苷能明显抑制HL-60/ADR细胞增殖,半数抑制浓度(IC50)约为28μmol/L;较低浓度黄芩苷即可抑制HL-60/ADR细胞集落的形成;Annexin V FITC/PI法检测到早期凋亡细胞,DNA片段化、TUNEL法检测到晚期凋亡细胞,细胞凋亡率呈浓度依赖性。细胞周期分析显示,与对照组比较,40μmol/L、80μmol/L浓度组细胞被阻滞于G0/G1期比率明显增高(P<0.01),S期细胞比率降低(P<0.01),各浓度组均检测到典型的亚二倍体峰(凋亡峰)。黄芩苷作用后HL-60/ADR细胞c-myc、bcl-2、hTERT、pim-2、mcl-1基因mRNA表达随着作用时间的延长而逐渐减少;p21基因mRNA表达随着作用时间的延长而逐渐升高。Western-Blot的结果显示c-myc、bcl-2、caspase-3(35kD)和PARP(116kD)蛋白的表达水平呈时间依赖性下降,而caspase-3(17kD、19kD)、PARP(85kD)及bad蛋白的表达则随着作用时间的延长逐渐升高。黄芩苷下调了HL-60/ADR细胞的PI3K/Akt/mTOR和MAPK信号通路蛋白中p-Akt、NF-κB、p-NF-κB、p-IκB-α、mTOR、p-mTOR、p-GSK-3β、p-MAPK的表达,而Akt、IκB-α、GSK-3β和MAPK的表达与对照组相比无明显改变。(2)黄芩苷能部分逆转HL-60/ADR细胞的多药耐药性,阿霉素和黄芩苷联合应用对HL-60/ADR细胞的增殖抑制率明显低于单用阿霉素者,阿霉素单用及联合黄芩苷对HL-60细胞的增殖抑制率没有影响。黄芩苷能下调mrp-1、lrp、GSTπ基因mRNA和mrp-1、GSTπ蛋白的表达,上调TopoⅡα和TopoⅡβ基因mRNA的表达(p<0.05)。而TopoⅠ基因在各组间表达无明显差别。同时观察到黄芩苷能使染上阿霉素荧光的HL-60/ADR细胞比例增加。(3)黄芩苷可抑制裸鼠HL-60细胞皮下移植瘤的生长,呈剂量依赖性。100mg/kg黄芩苷组和联合用药组(50mg/kg黄芩苷+2mg/kg VP16)的瘤块重量明显低于阴性对照组(p<0.01)。瘤组织病理组织学和透射电镜检查结果显示:黄芩苷用药组和联合用药组的肿瘤坏死和细胞凋亡现象较阴性对照组多见。黄芩苷可能通过抑制Akt活性,下调p-Akt、mTOR和p-mTOR的表达来抑制裸鼠异种移植瘤的增长;联合用药组中位生存期明显高于阴性对照组(p<0.05),提示黄芩苷与VP16具有协同抗HL-60细胞裸鼠异种移植瘤的作用。黄芩苷对裸鼠一般状况和体重无不良影响,对裸鼠无明显毒副作用。
结论(1)黄芩苷能有效抑制HL-60/ADR细胞增殖,诱导其凋亡。其机制可能与下调c-myc、bcl-2、hTERT、pim-2、mcl-1 mRNA和/或蛋白表达,上调p21、bad的表达有关。PI3K/Akt/mTOR、MAPK信号通路的改变可能参与了黄芩苷抑制HL-60/ADR细胞增殖、诱导凋亡的过程。(2)黄芩苷能部分逆转HL-60/ADR细胞的耐药性,其机制可能与下调mrp-1、lrp、GSTπ基因mRNA和/或蛋白表达,上调TopoⅡα和TopoⅡβ基因mRNA的表达,增加细胞内药物蓄积水平有关。(3)黄芩苷可抑制高致瘤HL-60细胞裸鼠异种移植瘤的生长,诱导瘤组织中HL-60细胞的凋亡,提高荷瘤裸鼠的中位生存期,其机制之一可能与下调PI3K/Akt/mTOR信号通路有关;黄芩苷与VP16联用具有协同抗HL-60细胞裸鼠异种移植瘤的作用。
Objective(1)To study the effects of baicalin on proliferation inhibition and apoptosis induction on adriamycin-resistant human myeloid leukemia cell line HL-60/ADR cells and on expressions of related apoptotic proteins and mRNA,and to study the change of PI3K/Akt/mTOR,MAPK signal pathway in baicalin-induced HL-60/ADR cells.(2)To investigate the effects of baicalin on the expression of drug-resistance related genes in HL-60/ADR cells and explore its reversal mechanism (.3)To observe the effects of baicalin on HL-60 cell xenografts in nude mice.
Methods(1)HL-60/ADR cells were in vitro cultured and exposed to baicalin at different dosages.Its proliferation inhibition and colony formation were detected by MTT assay and colony formation assay respectively.The cell apoptosis was tested by Annexin V FITC/PI double staining analysis, cell cycle analysis, DNA fragmentation and TUNEL labeling method.RT-PCR was used to analyze the c-myc, bcl-2, hTERT, pim-2, mcl-1 and p21 mRNA expression.The expressions of apoptosis related proteins and signaling molecular PI3K/AKT proteins were examined by western blot.(2)The effect of Adriamycin (ADR),Daunorubicin (DNR) ,Cytarabine (Ara-C) and Etoposide (VP16) on the proliferation of HL-60 and HL-60/ADR cells were observed by MTT assay.The inhibitory effects of all these chemotherapeutic agents used alone or incomebination with baicalin on the proliferation of HL-60 and HL-60/ADR cells were evaluated by MTT assay. The reversal fold of drug resistance was calculated. The expressions of mrp-1, lrp,GSTπ,TopoⅠ,TopoⅡαand TopoⅡβmRNA were measured by RT-PCR.The proteins level of mrp-1 and GSTπwere detected by western blot.The positive rate of ADR fluorescence was analyzed by flow cytometry.(3)Xenograft tumor model of HL-60 cell in nude mice was established,which was divided randomly into six groups:negative control group (5%NaHCO3 group),25mg/ kg baicalin group,50mg/kg baicalin group,100mg/kg baicalin group,combination group (50mg/kg baicalin+2mg/kg VP16),VP16 positive control group(4mg/kg). Nude mice growth state was observed, average weigh and inhibition rate of transplanted tumor were calculated, and the ultramicrostructure change of xenografts cells were tested by transmission electron microscope .Histopathology were used to observed the change of chief organs in nude mice.The expression of Akt, p-Akt, mTOR and p-mTOR proteins extracted from xenografts were detected by western blot. The effects of balcalin on survival rate and median survival time in nude mice with HL-60 cell xenografts were evaluated.
Result(s1)Baicalin effectively inhibited HL-60/ADR cells, proliferation, with an IC50 value of 28μmol/L.Cell colony formation was obviously inhibited by baicalin. Apoptosis occurred with dose dependent manners(20μmol/L, 40μmol/L,80μmol/L), and its earlier and later stages were both detected by Annexin V FITC/PI double staining analysis, DNA fragmentation and TUNEL labeling method. G0/G1 phase cell population increased while S phase cells decreased in 40μmol/L and 80μmol/L groups compared with control group(P<0.01).The typical hypo-diploid peak (apoptotic peak) appeared in each dose group.The mRNA expressions of c-myc, bcl-2, hTERT,pim-2 and mcl-1 in baicalin treated cells decreased in a time-dependent manner(12h,24h, 48h), while the p21 mRNA expression increased. Meanwhile, protein expressions of c-myc, bcl-2, caspase-3(35kD)and PARP(116kD)were down-regulated in a time- dependent manner, and the expressions of caspase-3(17kD,19kD),PARP(85kD) and bad were up-regulated.Moreover,western blot showed the expressions of p-Akt, NF-κB, p-NF-κB, p-IκB-α, mTOR, p-mTOR, p-GSK-3βand p-MAPK protein decreased in HL-60/ ADR cells after baicalin treatment , but the expression of Akt , IκB-α, GSK-3βand MAPK showed no difference compared to control group(.2)The multidrug resistance (MDR) in HL-60/ADR cells can be partially reversed by baicalin. Proliferation inhibition of ADR incombination with baicalin on the HL-60/ADR cells were significantly lower than that of ADR used alone, there was no difference of proliferation inhibition on HL-60 cells between ADR used alone and ADR incombination with baicalin.Baicalin could down-regulate the expression level of mrp-1, lrp,GSTπmRNA and mrp-1, GSTπprotein, and up-regulate TopoⅡαand TopoⅡβmRNA(p<0.05), but TopoⅠdid not change obviously. Furthermore,it was found that baicalin could elevated positive rate of ADR fluorescence in HL-60/ADR cells.(3)Baicalin could inhibit the growth of transplanted tumors in dose dependent manner.The transplanted tumor weight in 100 mg/kg baicalin group and combination group(50mg/kg baicalin+2mg/kg VP16) were significantly lower than that in negative control group(p<0.01) .There were more necrotic and apoptotic cells in baicalin treatment groups and combination group than that in negative control group by histopathology and transmission electron microscope methods.Baicalin could inhibit the proliferation of HL-60 cells in vivo by down-regulating the PI3K/Akt/mTOR signal pathway, where the expressions of p-Akt, mTOR and p-mTOR proteins decreased compared to negative control group, and Akt did not change significantly. Baicalin could prolong the median survival time of nude mice.Compared with negative control group, the median survival time in combination group was significantly different(p<0.05), which illustrated that baicalin combinated with VP16 have the synergistic effect on inhibiting growth of HL-60 cell xenografts in nude mice. The baicalin administration was well tolerated by the nude mice, and no significantly adverse effect was shown.
Conclusion(1)Baicalin could efficiently inhibit proliferation and induce apoptosis in HL-60/ADR cells, which could be correlated with the down-regulated expressions of c-myc,bcl-2,hTERT, mcl-1, and up-regulated expressions of p21and bad. PI3K/Akt /mTOR and MAPK signal pathways may have involved in the process of proliferation inhibition and apoptosis in HL-60/ADR cells induced by baicalin.(2)Baicalin could partially reverse the multidrug resistance of HL-60/ADR cell, and the reversal effect may be related with the reduction of the expression of mrp-1, lrp, GSTπmRNA or protein, increase of TopoⅡαand TopoⅡβmRNA expression level, and elevation of drug accumulation in HL-60/ADR cells.(3)Baicalin could inhibit growth and induce apoptosis of HL-60 cell xenografts in nude mice, and prolong its median survival time. The possible mechanisms may be related to inhibition of Akt activity and down- regulation ation of the PI3K/Akt /mTOR signal pathway. The combination of baicalin and VP16 shows a synergistic effect on inhibiting growth in HL-60 cell xenografts in nude mice.
引文
1.刘雄,高建德。黄芩研究进展[J]。甘肃中医学院学报,2007;24 (2):46-50。
2. Wang N,Tang LJ,Zhu GQ,et al.Apoptosis induced by baicalin involving up-regula- tion of P53 and bax in MCF-7 cell[J].J Asian Nat Prod Res,2008;10(12):1129- 1135.
3. Ikezoe T,Chen SS,Heber D,et al.Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest[J]. Prostate,2001;49(4):285-292.
4. Liu JJ, Huang TS, Cheng WF, et al. Baicalein and baicalin are potent inhibitors of angiogenesis:Inhibition of endothelial cell proliferation,migration and differentia- tion [J]. Int J Cancer, 2003;106(4):559-565.
5. Chao JI, Su WC, Liu HF. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT[J].Mol Cancer Ther,2007;6 (11):3039-3048.
6.陈步远,胡建达。黄芩苷作用HL-60细胞前后c-myc基因表达的变化[J]。白血病.淋巴瘤,2006;15(3):167-169。
7. Wang J, Wang H, Li Z, et al.c-Myc is required for maintenance of glioma cancer stem cells[J]. PLoS ONE, 2008;3(11):e3769.
8. Hoffman B,Liebermann DA.Apoptotic signal by c-MYC[J].Oncogene,2008;27(50): 6462-6472.
9. Wierstra I, Alves J. The c-myc promoter: still mystery and challenge[J].Adv Cancer Res, 2008;99:113-133.
10. Zhang X,Ge YL,Tian RH. The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo[J]. Cell Mol Biol Lett, 2009;14(2):305-318.
11.连晓岚,胡建达,郑志宏,等。大黄素诱导白血病937细胞凋亡及机制初探[J]。中国药理学通报,2007,23(10):1312-1316。
12. Ilievska Poposka B , Smickova S, Jovanovska Crvenkovska S, et, al. Bcl-2 as a prognostic factor for survival in small-cell lung cancer[J].Prilozi,2009;29(2):281- 294.
13. Sakai Y, Goodison S, Kusmartsev S,et,al.Bcl-2 mediated modulation of vasculari- zation in prostate cancer xenografts[J]. Prostate, 2009;69(5):459-470.
14. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects[J].Blood, 2008;111(7):3322-3330.
15. Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart [J].Am J Physiol Cell Physiol, 2007;292(1):C45-C51.
16. Antonsson B,Martinou JC.The Bcl-2 protein family[J].Exp Cell Res, 2000;256(1): 50-57.
17. Shieh DE, Cheng HY, Yen MH,et,al.Baicalin–induced apoptosis is mediated by Bcl-2-dependent,but not p53-dependent, passway human leukemia cell lines [J]. Am J Chin Med, 2006;34(2):245-261.
18. Holt SE,Glinsky VV, Ivanova AB, et,al. Resistance to apoptosis in human cells conferred by telomerase function and telomerest ability[J].Mol Carcinog,1999; 25(4): 241-248.
19. Cong Y,Shay JW. Actions of human telomerase beyond telomeres[J].Cell Res, 2008;18(7):725-732.
20. Bachmann M,Moroy T.The serine/threonine kinase Pim-1[J].Int J Biochem Ce1l Biol,2005;37(4):726-730.
21. Fox CJ,Hammerman PS,Cinalli RM,et a1.The serine/threonine kinase Pim-2 is a transcriptionally regulated apopototic inhibitor[J].Genes&Dev, 2003;17(15):1841- 1854.
22. Macdonald A,Campbell DG,Toth R,et a1.Pim kinases phosphorylate multiple sites on Bad and promote14-3-3 binding and dissociation from Bcl-XL[J].BMC Cell Biology,2006;7:1.
23. Pelengaris S,Khan M,Evan G.c-Myc:more than just a matter of life and death[J]. Nature Reviews,Cancer,2002;2(10):764-776.
24. Radhakrishnan SK,Felieiano CS,Najmabadi F,et a1.Constitutive expression ofE2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle[J]. Oncogene,2004;23(23):4173-4176.
25. Okuyama T,Maehara Y,Kabashima A,et a1.Combinede valuation of expressions of p53 and p2l proteins as prognostic factors for patients with gastriccarcinoma[J]. Oncology,2002;63(4):353-361.
26. Worf BB,Green DR.Suicidal Tendencies:Apoptotic Cell Death by Caspase Family Proteinase.J Biol Chem,1999;274(29):20049-20052.
27. Ivana Scovassi A,Diederich M.Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem Pharmacol, 2004;68(6):1041-1047.
28. Douglas A L,Faina B,Cindy J Y,et a1.Frequent mutation of the PIK3CA gene in ovarian and breast cancer.Clin Cancer Res,2005;11(8):2875-2878.
29. Oda K,Stokoe D,Taketani Y,et a1.High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma [J].Cancer Res,2005;65(23): 10669-10673.
30. Xu Q,Simpson SE,Scialla TJ,et a1.Survival of acute myeloid leukemia cells requires PI3 kinase activation[J]. Blood,2003;102(3):972-980.
31. Jucker M, Sudel K, Horn S, et a1. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositl 3-kinase in a Hodgkins lymphoma- derived cell line (CO) [J].Leukemia,2002;16(5):894-901.
32. Osaki M,Oshimura M,Ito H.P13K-Akt pathway:its functions and alterations in human cancer[J].Apoptosis,2004;9(6):667-676.
33. Song G,Ouyang G L,Bao S D.The activation of Akt/PKB signaling pathway and cell survival[J].J Cell Mol Med,2005;9(1):59-71.
34. Vandermoere F,El Yazidi-Belkoura I,Adriaenssens E,et a1.The Antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-KB activation induced via interaction between Akt and IKB kinase-B in breast cancer cells[J].Onco gene,2005;24(35):5482-5491.
35. Harikumar KB, Kunnumakkara AB, Ahn KS,et,al. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads tosuppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells[J].Blood,2009;113(9):2003-2013.
36. Ma Z, Otsuyama K, Liu S,et,al. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells[J].Blood,2005;105(8):3312- 3318.
37.黄秀兰,崔国辉,周克元。PI3K-Akt信号通路与肿瘤细胞凋亡关系的研究进展[J]。癌症,2008;27(3):331-336。
38. Marinov M, Ziogas A, Pardo OE,et,al.AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001[J].Clin Cancer Res, 2009;15(4):1277-1287.
39. Cross DA, Culbert AA, Chalmers KA, et,al.Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect neurons from death[J]. J Neurochem, 2001; 77(1): 94-102.
40. Lei S,Dubeykovskiy A,Chakladar A,et a1.The murine gastrin promoter is synergi- stically activated by transforming growth factor-beta/SMAD and Wnt signaling pathways[J].J Biol Chem,2004;279(41):42492-42502.
41. Karhadkar SS,Isaacs JT,BeachyPA,et a1.Hedgehog signalling in prostate regener- ation,neoplasia and metastasis[J].Nature,2004;43l(7001):707-7l2.
42.Ding VW,Chen RH,Mccormick F.Differential regulation of glycogen synthase kinase-3βby insulin and wnt signaling[J].J Biol Chem,2000;275(42):32475- 32481.
43. Doble BW,Woodgett JR.GSK-3:tricks of the trade for a multi-tasking kinase [J].J Cell Sci,2003;116(Pt 7):l175-1186.
44. Aline P,Blandine B,Marie G,et a1.Purification of GSK-3 by affinity chromato- graphy on immobilized axin[J].Protein Exp and Purifica,2000;20(3):394-404.
45. Dal Col J, Dolcetti R. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma[J]. Cell Cycle, 2008;7(18):2813-2816.
46. Fecher LA,Amaravadi RK,Flaherty KT.The MAPK pathway in melanoma[J].Curr Opin Oncol,2008;20(2):183-189.
47. Lawrence MC,Jivan A,Shao C,et a1.The roles of MAPKs in disease[J].Cell Res, 2008;18(4):436-442.
48. Daouti S,Wang H,Li WH,et,al.Characterization of a novel mitogen-activated protein ein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy [J].Cancer Res,2009;69(5):1924-1932.
49. Wilhelm SM,Carter C,Tang L,et a1.BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004;64 (19):7099-7109.
50. McLornan DP, McMullin MF, Johnston P,et,al. Molecular mechanisms of drug resistance in acute myeloid leukaemia[J].Expert Opin Drug Metab Toxicol,2007; 3(3):363-377.
51. Yu LJ,Matias J,Scudiero DA,et a1.P450 enzyme expression Patterns in the NCI human tumor cell line panel[J].Drug Metab Dispos,2001;29(3):304-312.
52. Liu FS,Jan YJ,Lai CR,et,al.Expression analysis of apoptosis-related markers TP53, BCL-2,BAX and c-MYC in female genital tract sarcomas[J].J Chin Med Assoc, 2008;71(12):628-634.
53. Arceci RJ. Can multidrug resistance mechanisms be modified [J]? Br J Haematol, 2000;110(2):285-291.
54. Oggionni M,Pilotti S,Suardi S,et a1.P53 gene status and response to topotecan -containing chemotherapy in advanced ovarian carcinoma[J].Oncology,2005;69 (2):154-158.
55. Sun C,Chan F, Briassouli P,et a1.Aurora kinase inhibition down-regulates NF- kappaB and sensitises tumour cells to chemotherapeutic agents [J].Biochem Biophys Res Commun,2007;352(1):220-225.
56. Kim DS,Park SS,Nam BH,et a1.Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation[J]. Cancer Res,2006;66(22):10936-10943.
57. Bentires-Alj M, Barbu V, Fillet M, et a1.NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells[J].Oncogene,2003;22(1):90-97.
58. Tazzari PL,Cappellini A,Ricci F,et a1.Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts[J]. Leukemia, 2007; 21(3):427-438.
59. Chiarini F, Del Sole M, Mongiorgi S, et a1.The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK- dependent mechanism[J]. Leukemia,2008;22(6):1106-1116.
60.Chen B,Jin F,Lu P,et a1.Efect of mitogen-activated protein kinase signal transduction pathway on muhidrug resistance induced by vincristine in gastric cancer cell line MGC803[J].World J Castroenterol,2004;10(6):795-799.
61. ZhaoY,You H,Yang Y,et a1.Distinctive regulation and function of PI3K/Akt and MAPKs in doxorubicln-induced apoptosis of human lung adenocarcinoma cells [J].J Cell Biochem,2004;91(3):621-632.
62. Wu CP,Calcagno AM,Ambudkar SV,et,al.Reversal of ABC drug transporter- mediated multidrug resistance in cancer cells: Evaluation of current strategies[J]. Curr Mol Pharmacol, 2008;1(2):93-105.
63. Kapoor P, Greipp PT, Morice WG,et,al.Anti-CD20 monoclonal antibody therapy in multiple myeloma[J]. Br J Haematol, 2008;141(2):135-148.
64. Hoffmann K, Mehrle S, Schmidt J, et,al. Interferon-alpha restitutes the chemosen- sitivity in pancreatic cancer[J]. Anticancer Res, 2008 ;28(3A):1499-1507.
65. Kaszubiak A, Holm PS, Lage H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes [J].Int J Oncol,2007;31(2):419-430.
66.魏民,张阳德,何剪太。姜黄素逆转肝癌耐药性实验研究[J]。中国现代医学杂志,2008;18(17):2441-2443。
67.陈宝安,苏爱玲,程坚,等。汉防己甲素对白血病耐药细胞株KS62/A02核因子KB表达的影响[J]。中西医结合学报,2008;6(9):956-959。
68. Shman T V,Savitskii V P,Potapnev M P,et a1.Study of expression and functionalactivity of P-GP membrane glyeoprotein in children with acute leukemia [J].Bull Exp Biol Med,2006;141(6):727-730.
69.TrnkováZ, BedrlíkováR, MarkováJ, et a1.Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia[J]. Neoplasma, 2007; 54 (5):383-390.
70. Ishikawa T, Kuo MT, Furuta K, et a1.A new aspect on glutathione-associated biological function of MRP/GS-X pump and its gene expression[J]. Cytotechnology, 1998;27(1-3):81-93.
71. Plasschaert SL,de Bont ES,Boezen M,et a1.Expression of multidrug resistance- associated proteins predicts prognosis in childhood and adult acute lympho blastic leukemia[J]. Clin Cancer Res, 2005;11(24 Pt 1):8661-8668.
72. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance[J].Cancer Res,1993;53(7):1475-1479.
73. Yasunami T, Wang YH, Tsuji K, et al. Multidrug resistance protein expression of adult T-cell leukemia/lymphoma[J]. Leuk Res,2007;31(4):465-470.
74. Huh HJ,Park CJ,Jang S,et a1.Prognostic significance of multidrug resistance gene 1(MDR1),multidrug resistance-related protein(MRP)and lung resistance protein (LRP) mRNA expression in acute leukemia[J].J Korean Med Sci,2006;21(2): 253 -258.
75. Albermann N,Sehmitz-Winnenthal F H,Zqraqqen K,et a1.Expression of the drug transporters MDRI/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG 2,and PXR in peripheral blood mononuelear cells and their relationship with the expression in intestine and liver[J].Bionchem Pharmaeol,2005;70(6):949-958.
76. Burger H,Foekens JA.RNA expresion of breast cancer resistance protein,lung resistance-related protein, multidrug resistance-associated proteins 1 and2, and multidrug resistance gene 1 in breast cancer:correlation with chemotherapeutic [J]. J Clin Cancer Res,2003;9(2):827-836.
77. Benderra Z,Faussat AM.Breast cancer resistance protein and P-glycoprotein in
149 adult acute myeloid leukemis[J].J Clin Cancer Res,2004;10(23):7896-7902.
78. Stanulla M, Sch?ffeler E, Arens S, et a1.GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia [J].Int J Hematol, 2005;81(1):39-44.
79. Chikamori K,Hill J E,Grabowski D R,et al.Downregulation of topoisomeraseI beta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest[J].Leukemia,2006;20 (10):1809 -l8l8.
80.杜芹,杨锡贵。肿瘤耐药机制及其逆转措施的研究[J]。实用癌症杂志,2008;23(4),427-429。
81. Uggla B,Tina E,Nahi H,et al.Topoisomerase IIalpha mRNA and protein express- ion vs in vitro drug resistance and clinical outcome in acute leukaemia[J].Int J Oncol, 2007;31(1):153-160.
82.田春艳,张凤春,林玉梅,等。中药功劳木逆转K562/ADM、MCF-7/ADM细胞的作用[J]。第四军医大学学报,2004;5(3):236-239。
83.谢长生,周维顺,郭勇,等。三根制剂对MDR细胞株逆转的研究[J]。实用中医药杂志,2003;19(3):115-117。
84. Kyo R, Nakahata N, Sakakibara I, et a1.Baicalin and baicalein, constituents of an important medicinal plant, inhibit intracellular Ca2+ elevation by reducing hospholipase C activity in C6 rat glioma cells[J].J Pharm Pharmacol,1998;50 (10): 1179-1182.
85. Miocinovic R, McCabe NP, Keck RW, et a1.In vivo and in vitro effect of aicalein on human prostate cancer cells[J]. Int J Oncol,2005;26(1):241-246.
1. Hsu SY,Hsueh AJ.Tissue-specific Bcl-2 protein partners in apoptosis:An ovarian paradigm[J].Physiol Rev,2000;80(2):593-614.
2. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects[J].Blood, 2008;,111(7):3322-3330.
3. Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart [J]. Am J Physiol Cell Physiol,2007;292(1):C45-C51.
4. Fletcher JI, Huang DC. Controlling the cell death mediators Bax and Bak: puzzles and conundrums[J].Cell Cycle, 2008;7(1):39-44.
5. Meulmeester E, Jochemsen AG. p53: a guide to apoptosis[J]. Curr Cancer Drug Targets, 2008;8(2):87-97.
6. Yu J, Zhang L.The transcriptional targets of p53 in apoptosis control[J]. Biochem Biophys Res Commun,2005;331(3):851-855.
7. Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression [J].Nucleic Acids Research,2007;35(22):7475-7484.
8. Kaghad M,Bonnet H,Yang A,et a1.Monallelically expressed gene related to p53 at lp36 a region frequently deleted in neuroblastoma and other human cancers[J].Cell, 1997;90(4):809-819.
9. Jost CA,Marin MC,Kaelin WG Jr.p73 is a simian [correction of human] p53-related protein that can induce apoptosis[J].Nature,1997;389(6647):191-194.
10. Wang XQ,Ongkeko w,LaIl AW,et a1.A possible role of p73 on the modulation of p53 level through MDM2[J]. Cancer Res,2001;61(4):1598-1603.
11. Rama S,Suresh Y,Rao A J.TGF betal induces multiple inde-pendent signals to regulate human trophoblastic differentiation:mechanistic insights[J].Mol Cell Endocrinol,2003;206(1-2):123-136.
12. Kim S J,Letterio J.Transforming growth factor-beta signaling in normal and malignant hematopoiesis[J].Leukemia,2003;17(9): 1731-1737.
13. Wierstra I,Alves J.The c-myc promoter:still mystery and challenge[J].Adv Cancer Res, 2008;99:113-333.
14. Gu L, Zhu N, Findley HW,et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2[J].Leukemia,2008;22(4):730-739.
15. Latoneu L,Kurki s,Htane K,et a1.p53 andmdm2 are regulated by PI-3-kinase on multiple levels under stress induced by UV radiation and proteasome dys function [J].Cell Signal,2003;15(1):95-102.
16. Bose I, Ghosh B. The p53-MDM2 network: from scillations to apoptosis[J]. J Biosci, 2007;32(5):991-997.
17. Fukuda S,Pelus L M.Survivin,a cancer target with an emerging role in normal adult tissues [J]. Mol Cancer Ther,2006;5(5):l087-l098.
18. Suzuki A,Ito T,Kawano H,et a1.Survivin initiates procaspase 3/p21 complex formation as a result of interaction with cdk4 to resist Fas-mediated cell death [J]. Oncogene,2000;19(10):1346-1353.
19. Blum R,Jacob-Himch J,Rechavi G,et a1.Suppression of survivin expression in glioblastoma cells by the Ras inhibitor famesylthiosalicylic acid promotes caspase-dependent apoptosis[J].Mol Cancer Ther,2006;5(9):2337-2347.
20. Barnes DJ,Melo JV.Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia [J]. Acta Haematol, 2002;108(4):180-202.
21. Rapozzi V, Cogoi S, Xodo LE. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells[J].Mol Cancer Ther, 2006;5(7):1683-1692.
22. Rowley PT,Keng Pc,Kosciolek BA.The effect of bcr/abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukaemia cells[J]. Leuk Res,1996;20:473-480.
23. Suzuki A,0bata S,Nakamurahida Y,et a1.Retraction: SADS:An new component of Fas-DISC is the accelerator for cell death signaling and is downregulated in patients with colon carcinoma [J].Nat Med,2001;7(6):749.
24.张东华,刘文励,张瑶珍主编。白血病基础与临床。中国医药科技出版社。P53。
25. Stirewalt DL,Radich JP.The role of Flt3 in haematopoietic malignancies [J].NatRev Cancer,2003;3(9):650-665.
26. Nakao M, Yokota S, Iwai T, Kaneko H, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia [J].Leukemia,1996;10(12):1911-1918.
27. Galluzzi L, Joza N, Tasdemir E, et al. No death without life: vital functions of apoptotic effectors [J]. Cell Death Differ, 2008;15(7):1113-1123.
28. Blum ES,Driscoll M,Shaham S. oncanonical cell death programs in the nematode Caenorhabditis elegans [J].Cell Death Differ, 2008;15(7):1124-1131.
29. Kim CM, Koike K, Saito I, et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice [J]. Nature,1991;351:317-320.
30.Yokosuka O, Arai M. Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B[J].Med Mol Morphol, 2006;39(3):113-120.
31. Galluzzi L,Brenner C,Morselli E,et al. iral control of mitochondrial apoptosis[J]. PLoS Pathog, 2008;;4(5):e1000018.
32. Ferri KF, Jacotot E, Blanco J,et al. Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of mitochondria and caspases[J]. J Exp Med,2000;192(8):1081-1092.
33. Poncet D,Pauleau AL,Szabadkai G,et al.Cytopathic effects of the cytomegalovirus -encoded apoptosis inhibitory protein vMIA[J].J Cell Biol,2006;174(7):985–996.
2. Wang N,Tang LJ,Zhu GQ,et al.Apoptosis induced by baicalin involving up-regula- tion of P53 and bax in MCF-7 cell[J].J Asian Nat Prod Res,2008;10(12):1129- 1135.
3. Ikezoe T,Chen SS,Heber D,et al.Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest[J]. Prostate,2001;49(4):285-292.
4. Liu JJ, Huang TS, Cheng WF, et al. Baicalein and baicalin are potent inhibitors of angiogenesis:Inhibition of endothelial cell proliferation,migration and differentia- tion [J]. Int J Cancer, 2003;106(4):559-565.
5. Chao JI, Su WC, Liu HF. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT[J].Mol Cancer Ther,2007;6 (11):3039-3048.
6.陈步远,胡建达。黄芩苷作用HL-60细胞前后c-myc基因表达的变化[J]。白血病.淋巴瘤,2006;15(3):167-169。
7. Wang J, Wang H, Li Z, et al.c-Myc is required for maintenance of glioma cancer stem cells[J]. PLoS ONE, 2008;3(11):e3769.
8. Hoffman B,Liebermann DA.Apoptotic signal by c-MYC[J].Oncogene,2008;27(50): 6462-6472.
9. Wierstra I, Alves J. The c-myc promoter: still mystery and challenge[J].Adv Cancer Res, 2008;99:113-133.
10. Zhang X,Ge YL,Tian RH. The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo[J]. Cell Mol Biol Lett, 2009;14(2):305-318.
11.连晓岚,胡建达,郑志宏,等。大黄素诱导白血病937细胞凋亡及机制初探[J]。中国药理学通报,2007,23(10):1312-1316。
12. Ilievska Poposka B , Smickova S, Jovanovska Crvenkovska S, et, al. Bcl-2 as a prognostic factor for survival in small-cell lung cancer[J].Prilozi,2009;29(2):281- 294.
13. Sakai Y, Goodison S, Kusmartsev S,et,al.Bcl-2 mediated modulation of vasculari- zation in prostate cancer xenografts[J]. Prostate, 2009;69(5):459-470.
14. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects[J].Blood, 2008;111(7):3322-3330.
15. Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart [J].Am J Physiol Cell Physiol, 2007;292(1):C45-C51.
16. Antonsson B,Martinou JC.The Bcl-2 protein family[J].Exp Cell Res, 2000;256(1): 50-57.
17. Shieh DE, Cheng HY, Yen MH,et,al.Baicalin–induced apoptosis is mediated by Bcl-2-dependent,but not p53-dependent, passway human leukemia cell lines [J]. Am J Chin Med, 2006;34(2):245-261.
18. Holt SE,Glinsky VV, Ivanova AB, et,al. Resistance to apoptosis in human cells conferred by telomerase function and telomerest ability[J].Mol Carcinog,1999; 25(4): 241-248.
19. Cong Y,Shay JW. Actions of human telomerase beyond telomeres[J].Cell Res, 2008;18(7):725-732.
20. Bachmann M,Moroy T.The serine/threonine kinase Pim-1[J].Int J Biochem Ce1l Biol,2005;37(4):726-730.
21. Fox CJ,Hammerman PS,Cinalli RM,et a1.The serine/threonine kinase Pim-2 is a transcriptionally regulated apopototic inhibitor[J].Genes&Dev, 2003;17(15):1841- 1854.
22. Macdonald A,Campbell DG,Toth R,et a1.Pim kinases phosphorylate multiple sites on Bad and promote14-3-3 binding and dissociation from Bcl-XL[J].BMC Cell Biology,2006;7:1.
23. Pelengaris S,Khan M,Evan G.c-Myc:more than just a matter of life and death[J]. Nature Reviews,Cancer,2002;2(10):764-776.
24. Radhakrishnan SK,Felieiano CS,Najmabadi F,et a1.Constitutive expression ofE2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle[J]. Oncogene,2004;23(23):4173-4176.
25. Okuyama T,Maehara Y,Kabashima A,et a1.Combinede valuation of expressions of p53 and p2l proteins as prognostic factors for patients with gastriccarcinoma[J]. Oncology,2002;63(4):353-361.
26. Worf BB,Green DR.Suicidal Tendencies:Apoptotic Cell Death by Caspase Family Proteinase.J Biol Chem,1999;274(29):20049-20052.
27. Ivana Scovassi A,Diederich M.Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem Pharmacol, 2004;68(6):1041-1047.
28. Douglas A L,Faina B,Cindy J Y,et a1.Frequent mutation of the PIK3CA gene in ovarian and breast cancer.Clin Cancer Res,2005;11(8):2875-2878.
29. Oda K,Stokoe D,Taketani Y,et a1.High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma [J].Cancer Res,2005;65(23): 10669-10673.
30. Xu Q,Simpson SE,Scialla TJ,et a1.Survival of acute myeloid leukemia cells requires PI3 kinase activation[J]. Blood,2003;102(3):972-980.
31. Jucker M, Sudel K, Horn S, et a1. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositl 3-kinase in a Hodgkins lymphoma- derived cell line (CO) [J].Leukemia,2002;16(5):894-901.
32. Osaki M,Oshimura M,Ito H.P13K-Akt pathway:its functions and alterations in human cancer[J].Apoptosis,2004;9(6):667-676.
33. Song G,Ouyang G L,Bao S D.The activation of Akt/PKB signaling pathway and cell survival[J].J Cell Mol Med,2005;9(1):59-71.
34. Vandermoere F,El Yazidi-Belkoura I,Adriaenssens E,et a1.The Antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-KB activation induced via interaction between Akt and IKB kinase-B in breast cancer cells[J].Onco gene,2005;24(35):5482-5491.
35. Harikumar KB, Kunnumakkara AB, Ahn KS,et,al. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads tosuppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells[J].Blood,2009;113(9):2003-2013.
36. Ma Z, Otsuyama K, Liu S,et,al. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells[J].Blood,2005;105(8):3312- 3318.
37.黄秀兰,崔国辉,周克元。PI3K-Akt信号通路与肿瘤细胞凋亡关系的研究进展[J]。癌症,2008;27(3):331-336。
38. Marinov M, Ziogas A, Pardo OE,et,al.AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001[J].Clin Cancer Res, 2009;15(4):1277-1287.
39. Cross DA, Culbert AA, Chalmers KA, et,al.Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect neurons from death[J]. J Neurochem, 2001; 77(1): 94-102.
40. Lei S,Dubeykovskiy A,Chakladar A,et a1.The murine gastrin promoter is synergi- stically activated by transforming growth factor-beta/SMAD and Wnt signaling pathways[J].J Biol Chem,2004;279(41):42492-42502.
41. Karhadkar SS,Isaacs JT,BeachyPA,et a1.Hedgehog signalling in prostate regener- ation,neoplasia and metastasis[J].Nature,2004;43l(7001):707-7l2.
42.Ding VW,Chen RH,Mccormick F.Differential regulation of glycogen synthase kinase-3βby insulin and wnt signaling[J].J Biol Chem,2000;275(42):32475- 32481.
43. Doble BW,Woodgett JR.GSK-3:tricks of the trade for a multi-tasking kinase [J].J Cell Sci,2003;116(Pt 7):l175-1186.
44. Aline P,Blandine B,Marie G,et a1.Purification of GSK-3 by affinity chromato- graphy on immobilized axin[J].Protein Exp and Purifica,2000;20(3):394-404.
45. Dal Col J, Dolcetti R. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma[J]. Cell Cycle, 2008;7(18):2813-2816.
46. Fecher LA,Amaravadi RK,Flaherty KT.The MAPK pathway in melanoma[J].Curr Opin Oncol,2008;20(2):183-189.
47. Lawrence MC,Jivan A,Shao C,et a1.The roles of MAPKs in disease[J].Cell Res, 2008;18(4):436-442.
48. Daouti S,Wang H,Li WH,et,al.Characterization of a novel mitogen-activated protein ein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy [J].Cancer Res,2009;69(5):1924-1932.
49. Wilhelm SM,Carter C,Tang L,et a1.BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004;64 (19):7099-7109.
50. McLornan DP, McMullin MF, Johnston P,et,al. Molecular mechanisms of drug resistance in acute myeloid leukaemia[J].Expert Opin Drug Metab Toxicol,2007; 3(3):363-377.
51. Yu LJ,Matias J,Scudiero DA,et a1.P450 enzyme expression Patterns in the NCI human tumor cell line panel[J].Drug Metab Dispos,2001;29(3):304-312.
52. Liu FS,Jan YJ,Lai CR,et,al.Expression analysis of apoptosis-related markers TP53, BCL-2,BAX and c-MYC in female genital tract sarcomas[J].J Chin Med Assoc, 2008;71(12):628-634.
53. Arceci RJ. Can multidrug resistance mechanisms be modified [J]? Br J Haematol, 2000;110(2):285-291.
54. Oggionni M,Pilotti S,Suardi S,et a1.P53 gene status and response to topotecan -containing chemotherapy in advanced ovarian carcinoma[J].Oncology,2005;69 (2):154-158.
55. Sun C,Chan F, Briassouli P,et a1.Aurora kinase inhibition down-regulates NF- kappaB and sensitises tumour cells to chemotherapeutic agents [J].Biochem Biophys Res Commun,2007;352(1):220-225.
56. Kim DS,Park SS,Nam BH,et a1.Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation[J]. Cancer Res,2006;66(22):10936-10943.
57. Bentires-Alj M, Barbu V, Fillet M, et a1.NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells[J].Oncogene,2003;22(1):90-97.
58. Tazzari PL,Cappellini A,Ricci F,et a1.Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts[J]. Leukemia, 2007; 21(3):427-438.
59. Chiarini F, Del Sole M, Mongiorgi S, et a1.The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK- dependent mechanism[J]. Leukemia,2008;22(6):1106-1116.
60.Chen B,Jin F,Lu P,et a1.Efect of mitogen-activated protein kinase signal transduction pathway on muhidrug resistance induced by vincristine in gastric cancer cell line MGC803[J].World J Castroenterol,2004;10(6):795-799.
61. ZhaoY,You H,Yang Y,et a1.Distinctive regulation and function of PI3K/Akt and MAPKs in doxorubicln-induced apoptosis of human lung adenocarcinoma cells [J].J Cell Biochem,2004;91(3):621-632.
62. Wu CP,Calcagno AM,Ambudkar SV,et,al.Reversal of ABC drug transporter- mediated multidrug resistance in cancer cells: Evaluation of current strategies[J]. Curr Mol Pharmacol, 2008;1(2):93-105.
63. Kapoor P, Greipp PT, Morice WG,et,al.Anti-CD20 monoclonal antibody therapy in multiple myeloma[J]. Br J Haematol, 2008;141(2):135-148.
64. Hoffmann K, Mehrle S, Schmidt J, et,al. Interferon-alpha restitutes the chemosen- sitivity in pancreatic cancer[J]. Anticancer Res, 2008 ;28(3A):1499-1507.
65. Kaszubiak A, Holm PS, Lage H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes [J].Int J Oncol,2007;31(2):419-430.
66.魏民,张阳德,何剪太。姜黄素逆转肝癌耐药性实验研究[J]。中国现代医学杂志,2008;18(17):2441-2443。
67.陈宝安,苏爱玲,程坚,等。汉防己甲素对白血病耐药细胞株KS62/A02核因子KB表达的影响[J]。中西医结合学报,2008;6(9):956-959。
68. Shman T V,Savitskii V P,Potapnev M P,et a1.Study of expression and functionalactivity of P-GP membrane glyeoprotein in children with acute leukemia [J].Bull Exp Biol Med,2006;141(6):727-730.
69.TrnkováZ, BedrlíkováR, MarkováJ, et a1.Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia[J]. Neoplasma, 2007; 54 (5):383-390.
70. Ishikawa T, Kuo MT, Furuta K, et a1.A new aspect on glutathione-associated biological function of MRP/GS-X pump and its gene expression[J]. Cytotechnology, 1998;27(1-3):81-93.
71. Plasschaert SL,de Bont ES,Boezen M,et a1.Expression of multidrug resistance- associated proteins predicts prognosis in childhood and adult acute lympho blastic leukemia[J]. Clin Cancer Res, 2005;11(24 Pt 1):8661-8668.
72. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance[J].Cancer Res,1993;53(7):1475-1479.
73. Yasunami T, Wang YH, Tsuji K, et al. Multidrug resistance protein expression of adult T-cell leukemia/lymphoma[J]. Leuk Res,2007;31(4):465-470.
74. Huh HJ,Park CJ,Jang S,et a1.Prognostic significance of multidrug resistance gene 1(MDR1),multidrug resistance-related protein(MRP)and lung resistance protein (LRP) mRNA expression in acute leukemia[J].J Korean Med Sci,2006;21(2): 253 -258.
75. Albermann N,Sehmitz-Winnenthal F H,Zqraqqen K,et a1.Expression of the drug transporters MDRI/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG 2,and PXR in peripheral blood mononuelear cells and their relationship with the expression in intestine and liver[J].Bionchem Pharmaeol,2005;70(6):949-958.
76. Burger H,Foekens JA.RNA expresion of breast cancer resistance protein,lung resistance-related protein, multidrug resistance-associated proteins 1 and2, and multidrug resistance gene 1 in breast cancer:correlation with chemotherapeutic [J]. J Clin Cancer Res,2003;9(2):827-836.
77. Benderra Z,Faussat AM.Breast cancer resistance protein and P-glycoprotein in
149 adult acute myeloid leukemis[J].J Clin Cancer Res,2004;10(23):7896-7902.
78. Stanulla M, Sch?ffeler E, Arens S, et a1.GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia [J].Int J Hematol, 2005;81(1):39-44.
79. Chikamori K,Hill J E,Grabowski D R,et al.Downregulation of topoisomeraseI beta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest[J].Leukemia,2006;20 (10):1809 -l8l8.
80.杜芹,杨锡贵。肿瘤耐药机制及其逆转措施的研究[J]。实用癌症杂志,2008;23(4),427-429。
81. Uggla B,Tina E,Nahi H,et al.Topoisomerase IIalpha mRNA and protein express- ion vs in vitro drug resistance and clinical outcome in acute leukaemia[J].Int J Oncol, 2007;31(1):153-160.
82.田春艳,张凤春,林玉梅,等。中药功劳木逆转K562/ADM、MCF-7/ADM细胞的作用[J]。第四军医大学学报,2004;5(3):236-239。
83.谢长生,周维顺,郭勇,等。三根制剂对MDR细胞株逆转的研究[J]。实用中医药杂志,2003;19(3):115-117。
84. Kyo R, Nakahata N, Sakakibara I, et a1.Baicalin and baicalein, constituents of an important medicinal plant, inhibit intracellular Ca2+ elevation by reducing hospholipase C activity in C6 rat glioma cells[J].J Pharm Pharmacol,1998;50 (10): 1179-1182.
85. Miocinovic R, McCabe NP, Keck RW, et a1.In vivo and in vitro effect of aicalein on human prostate cancer cells[J]. Int J Oncol,2005;26(1):241-246.
1. Hsu SY,Hsueh AJ.Tissue-specific Bcl-2 protein partners in apoptosis:An ovarian paradigm[J].Physiol Rev,2000;80(2):593-614.
2. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects[J].Blood, 2008;,111(7):3322-3330.
3. Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart [J]. Am J Physiol Cell Physiol,2007;292(1):C45-C51.
4. Fletcher JI, Huang DC. Controlling the cell death mediators Bax and Bak: puzzles and conundrums[J].Cell Cycle, 2008;7(1):39-44.
5. Meulmeester E, Jochemsen AG. p53: a guide to apoptosis[J]. Curr Cancer Drug Targets, 2008;8(2):87-97.
6. Yu J, Zhang L.The transcriptional targets of p53 in apoptosis control[J]. Biochem Biophys Res Commun,2005;331(3):851-855.
7. Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression [J].Nucleic Acids Research,2007;35(22):7475-7484.
8. Kaghad M,Bonnet H,Yang A,et a1.Monallelically expressed gene related to p53 at lp36 a region frequently deleted in neuroblastoma and other human cancers[J].Cell, 1997;90(4):809-819.
9. Jost CA,Marin MC,Kaelin WG Jr.p73 is a simian [correction of human] p53-related protein that can induce apoptosis[J].Nature,1997;389(6647):191-194.
10. Wang XQ,Ongkeko w,LaIl AW,et a1.A possible role of p73 on the modulation of p53 level through MDM2[J]. Cancer Res,2001;61(4):1598-1603.
11. Rama S,Suresh Y,Rao A J.TGF betal induces multiple inde-pendent signals to regulate human trophoblastic differentiation:mechanistic insights[J].Mol Cell Endocrinol,2003;206(1-2):123-136.
12. Kim S J,Letterio J.Transforming growth factor-beta signaling in normal and malignant hematopoiesis[J].Leukemia,2003;17(9): 1731-1737.
13. Wierstra I,Alves J.The c-myc promoter:still mystery and challenge[J].Adv Cancer Res, 2008;99:113-333.
14. Gu L, Zhu N, Findley HW,et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2[J].Leukemia,2008;22(4):730-739.
15. Latoneu L,Kurki s,Htane K,et a1.p53 andmdm2 are regulated by PI-3-kinase on multiple levels under stress induced by UV radiation and proteasome dys function [J].Cell Signal,2003;15(1):95-102.
16. Bose I, Ghosh B. The p53-MDM2 network: from scillations to apoptosis[J]. J Biosci, 2007;32(5):991-997.
17. Fukuda S,Pelus L M.Survivin,a cancer target with an emerging role in normal adult tissues [J]. Mol Cancer Ther,2006;5(5):l087-l098.
18. Suzuki A,Ito T,Kawano H,et a1.Survivin initiates procaspase 3/p21 complex formation as a result of interaction with cdk4 to resist Fas-mediated cell death [J]. Oncogene,2000;19(10):1346-1353.
19. Blum R,Jacob-Himch J,Rechavi G,et a1.Suppression of survivin expression in glioblastoma cells by the Ras inhibitor famesylthiosalicylic acid promotes caspase-dependent apoptosis[J].Mol Cancer Ther,2006;5(9):2337-2347.
20. Barnes DJ,Melo JV.Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia [J]. Acta Haematol, 2002;108(4):180-202.
21. Rapozzi V, Cogoi S, Xodo LE. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells[J].Mol Cancer Ther, 2006;5(7):1683-1692.
22. Rowley PT,Keng Pc,Kosciolek BA.The effect of bcr/abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukaemia cells[J]. Leuk Res,1996;20:473-480.
23. Suzuki A,0bata S,Nakamurahida Y,et a1.Retraction: SADS:An new component of Fas-DISC is the accelerator for cell death signaling and is downregulated in patients with colon carcinoma [J].Nat Med,2001;7(6):749.
24.张东华,刘文励,张瑶珍主编。白血病基础与临床。中国医药科技出版社。P53。
25. Stirewalt DL,Radich JP.The role of Flt3 in haematopoietic malignancies [J].NatRev Cancer,2003;3(9):650-665.
26. Nakao M, Yokota S, Iwai T, Kaneko H, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia [J].Leukemia,1996;10(12):1911-1918.
27. Galluzzi L, Joza N, Tasdemir E, et al. No death without life: vital functions of apoptotic effectors [J]. Cell Death Differ, 2008;15(7):1113-1123.
28. Blum ES,Driscoll M,Shaham S. oncanonical cell death programs in the nematode Caenorhabditis elegans [J].Cell Death Differ, 2008;15(7):1124-1131.
29. Kim CM, Koike K, Saito I, et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice [J]. Nature,1991;351:317-320.
30.Yokosuka O, Arai M. Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B[J].Med Mol Morphol, 2006;39(3):113-120.
31. Galluzzi L,Brenner C,Morselli E,et al. iral control of mitochondrial apoptosis[J]. PLoS Pathog, 2008;;4(5):e1000018.
32. Ferri KF, Jacotot E, Blanco J,et al. Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of mitochondria and caspases[J]. J Exp Med,2000;192(8):1081-1092.
33. Poncet D,Pauleau AL,Szabadkai G,et al.Cytopathic effects of the cytomegalovirus -encoded apoptosis inhibitory protein vMIA[J].J Cell Biol,2006;174(7):985–996.